NEW YORK (GenomeWeb News) – Compugen has received a letter from Nasdaq stating that the firm is currently not in compliance with listing regulations.

The Tel Aviv-based company said that it received the letter on May 28. The firm is not in compliance with regulations that state that it must have at least $10 million in stockholders' equity. As of March 31, Compugen had stockholders' equity of around $8.9 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Alnylam's RNAi-based therapy Onpattro, according to Stat News.

Harvard Medical School's Seth Cassel and Cigall Kadoch argue in a Baltimore Sun op-ed that the recent TAILORx trial shows the potential of genomic-based medicine.

Researchers in the UK are working on using gene drives to control malaria-carrying mosquitoes, the Telegraph reports.

In PLOS this week: genetic architecture mediating gene expression, metabolomic patterns in multiple myeloma, and more.